© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
February 13, 2021
Based on findings from the phase 3 CheckMate 9ER trial, the FDA approved nivolumab/cabozantinib for use in the first-line setting for patients with advanced RCC.